PL2956772T3 - Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta - Google Patents

Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta

Info

Publication number
PL2956772T3
PL2956772T3 PL14752032T PL14752032T PL2956772T3 PL 2956772 T3 PL2956772 T3 PL 2956772T3 PL 14752032 T PL14752032 T PL 14752032T PL 14752032 T PL14752032 T PL 14752032T PL 2956772 T3 PL2956772 T3 PL 2956772T3
Authority
PL
Poland
Prior art keywords
ards
patient
monitor
development
treatment
Prior art date
Application number
PL14752032T
Other languages
English (en)
Inventor
Mikael Maksimow
Marko Salmi
Markku Jalkanen
Sirpa Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of PL2956772T3 publication Critical patent/PL2956772T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
PL14752032T 2013-02-14 2014-01-22 Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta PL2956772T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20130049 2013-02-14
PCT/FI2014/050051 WO2014125164A1 (en) 2013-02-14 2014-01-22 A method for determining acute respiratory distress syndrome (ards) related biomarkers, a method to monitor the development and treatment of ards in a patient
EP14752032.4A EP2956772B1 (en) 2013-02-14 2014-01-22 A method for determining acute respiratory distress syndrome (ards) related biomarkers, a method to monitor the development and treatment of ards in a patient

Publications (1)

Publication Number Publication Date
PL2956772T3 true PL2956772T3 (pl) 2018-12-31

Family

ID=51353514

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14752032T PL2956772T3 (pl) 2013-02-14 2014-01-22 Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta

Country Status (17)

Country Link
US (1) US10247730B2 (pl)
EP (1) EP2956772B1 (pl)
JP (1) JP6337020B2 (pl)
KR (1) KR102121369B1 (pl)
CN (1) CN105164535B (pl)
AU (1) AU2014217753B2 (pl)
BR (1) BR112015018213B1 (pl)
CA (1) CA2898111C (pl)
DK (1) DK2956772T3 (pl)
ES (1) ES2683854T3 (pl)
HU (1) HUE038959T2 (pl)
LT (1) LT2956772T (pl)
PL (1) PL2956772T3 (pl)
PT (1) PT2956772T (pl)
SI (1) SI2956772T1 (pl)
WO (1) WO2014125164A1 (pl)
ZA (1) ZA201505386B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506889A (ja) 2011-02-18 2014-03-20 ステムディーアール インク. Sirt1発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
KR101949380B1 (ko) 2016-03-31 2019-02-19 (주) 인텍바이오 광산화 증폭을 이용한 고감도 바이오마커 정량 방법
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018204509A1 (en) * 2017-05-02 2018-11-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Predictive factors for acute respiratory distress syndrome
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
CA3096674A1 (en) * 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
WO2021152595A1 (en) * 2020-01-29 2021-08-05 Memed Diagnostics Ltd. Methods of diagnosing and classifying viral infections
WO2021250267A1 (en) * 2020-06-11 2021-12-16 Scailyte Ag A method for early detection of propensity to severe clinical manifestations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190872B1 (en) 1994-05-06 2001-02-20 Gus J. Slotman Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method
JP2002220343A (ja) * 2001-01-26 2002-08-09 Toray Ind Inc びまん性肺疾患延命剤
WO2003038444A2 (en) * 2001-10-31 2003-05-08 Pfizer Products Inc. Biomarkers of liver function
US20040072237A1 (en) * 2001-12-26 2004-04-15 Barry Schweitzer Use of cytokines secreted by dendritic cells
GB0414798D0 (en) * 2004-07-01 2004-08-04 Paradigm Therapeutics Ltd Receptor
WO2006039819A1 (en) * 2004-10-15 2006-04-20 St. Michael's Hospital Markers of lung injury
CN103145837A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
DE102006046411A1 (de) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von akutem Lungenversagen (ALI)
FI20070795A0 (fi) 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ, インコーポレイテッド 抗cd200抗体を用いたヒトの処置における免疫調節効果のバイオマーカー

Also Published As

Publication number Publication date
PT2956772T (pt) 2018-10-19
JP6337020B2 (ja) 2018-06-06
ZA201505386B (en) 2021-09-29
KR20150118107A (ko) 2015-10-21
LT2956772T (lt) 2018-10-25
WO2014125164A1 (en) 2014-08-21
BR112015018213A8 (pt) 2019-11-05
US20150377885A1 (en) 2015-12-31
HUE038959T2 (hu) 2018-12-28
SI2956772T1 (sl) 2018-11-30
BR112015018213A2 (pt) 2017-07-18
EP2956772A4 (en) 2016-09-14
KR102121369B1 (ko) 2020-06-11
AU2014217753A1 (en) 2015-07-23
CN105164535B (zh) 2018-04-10
HK1219130A1 (en) 2017-03-24
EP2956772B1 (en) 2018-05-30
EP2956772A1 (en) 2015-12-23
HK1218954A1 (zh) 2017-03-17
DK2956772T3 (en) 2018-08-13
JP2016513253A (ja) 2016-05-12
BR112015018213B1 (pt) 2022-12-20
CN105164535A (zh) 2015-12-16
CA2898111C (en) 2022-02-15
CA2898111A1 (en) 2014-08-21
AU2014217753B2 (en) 2018-07-05
US10247730B2 (en) 2019-04-02
ES2683854T3 (es) 2018-09-28

Similar Documents

Publication Publication Date Title
ZA201505386B (en) A method for determining acute respiratory distress syndrome (ards) related biomarkers, a method to monitor the development and treatment of ards in a patient
ZA201507560B (en) Device and method for determining the blood oxygen saturation of a subject
GB201402759D0 (en) A method and apparatus for determining the location of a medical instrument with respect to ultrasound imaging, and a medical instrument to facilitatesuch
IL244593A0 (en) Latency measurement and system and method for testing
PL4254209T3 (pl) Sposób, aparat i system do pomiaru opóźnienia w fizycznej jednostce obwodu
EP2967358A4 (en) OPTICAL TOMOGRAPHIC SENSOR AND APPARATUS AND ASSOCIATED METHODS
PT3967143T (pt) Dispositivo de adição de gás para tratamento sanguíneo e método correspondente
GB201311314D0 (en) Apparatus and method for performing photoacoustic tomography
PL2941195T3 (pl) Urządzenie do pomiaru analitów w skórze
EP2850428A4 (en) METHOD AND DEVICE FOR ANALYSIS OF ACETONE IN BREATH
GB201513356D0 (en) Method and device for determining the geometry of structures by means of computer tomography
GB201316566D0 (en) Apparatus and Method for User Exercise Monitoring
SG11201501208QA (en) Method and device for quantifying heart rate variability (hrv) coherence
IL244327B (en) Method and system for measuring breath analyte
PT2999402T (pt) Sistema de medição e método para medir parâmetros num tecido corporal
SG11201600083YA (en) Method and system for measuring oxyhemoglobin saturation in blood
GB201400730D0 (en) X-ray data processing appartus, x-ray data processing method, and x-ray data processing program
GB2519400B (en) Apparatus for blood concentration
GB201312720D0 (en) An apparatus, method and computer program for detecting physiological parameters
EP2702958A4 (en) DENTAL TREATMENT DIAGNOSTIC PROCEDURE, METHOD FOR CALCULATING DETERMINATION INDICATORS, PROGRAM THEREFOR AND COMPUTER THEREWITH
GB2509955B (en) Methods, apparatus and computer programs for use in measurement reporting
PL2970463T3 (pl) Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
GB2509601B (en) Analysis method, analysis apparatus and analysis program
EP2858561A4 (en) DEVICE, METHOD AND SOFTWARE FOR MEASURING EXPIRY CAPACITY
GB201523061D0 (en) Apparatus and method for monitoring transactions involving a conserved resource